Email this article 
Expanding the horizons of antiplatelet therapy. A pilot study of the antiplatelet properties of a new tropane alkaloid
- Authors: Mirzoian R.S.1, Shabalina A.A.2, Gan’shina T.S.1, Kurdyumov I.N.1, Turilova A.I.1, Kostochka L.M.1, Kozlov A.V.2, Annushkin V.A.2, Kornilova A.A.2, Tanashyan M.M.2
-
Affiliations:
- Research Zakusov Institute of Pharmacology
- Research Center of Neurology
- Issue: Vol 14, No 3 (2020)
- Pages: 53-59
- Section: Original articles
- URL: https://annaly-nevrologii.com/journal/pathID/article/view/684
- DOI: https://doi.org/10.25692/ACEN.2020.3.7
- ID: 684
Cite item
Full Text
Abstract
Introduction. The article discusses the search for new and highly effective drugs for the prevention and treatment of cerebrovascular disease. The aim was to examine the effect of the acyl hydrazone tropane derivative on individual platelet aggregation (PA) sensitivity in in vitro studies.
Results. We present the results of a pilot study on the effect of a new acyl hydrazone tropane derivative — acyl hydrazone (2,3,4-trimethoxy-N'-(8-methyl-8-azabicyclo [3.2.1.] octane-3-ylidene) benzohydrazide hydrochloride on PA properties in vitro in healthy volunteers and in patients with chronic cerebrovascular disease.
Conclusion. The studied compound has a pronounced ability to suppress PA when administered intravenously in vivo in two concentrations, equivalent to doses of 10 and 100 mg/kg, and its effect is superior to the comparator acetylsalicylic acid, which is used in clinical practice as an antiplatelet drug.
About the authors
Ruben S. Mirzoian
Research Zakusov Institute of Pharmacology
Author for correspondence.
Email: cerebropharm@mail.ru
Russian Federation, Moscow
Alla A. Shabalina
Research Center of Neurology
Email: cerebropharm@mail.ru
Russian Federation, Moscow
Tamara S. Gan’shina
Research Zakusov Institute of Pharmacology
Email: cerebropharm@mail.ru
Russian Federation, Moscow
Il'ya N. Kurdyumov
Research Zakusov Institute of Pharmacology
Email: cerebropharm@mail.ru
Russian Federation, Moscow
Antonina I. Turilova
Research Zakusov Institute of Pharmacology
Email: cerebropharm@mail.ru
Russian Federation, Moscow
Leonid M. Kostochka
Research Zakusov Institute of Pharmacology
Email: cerebropharm@mail.ru
Russian Federation, Moscow
Anton V. Kozlov
Research Center of Neurology
Email: cerebropharm@mail.ru
Russian Federation, Moscow
Vladislav A. Annushkin
Research Center of Neurology
Email: cerebropharm@mail.ru
Russian Federation, Moscow
Anastasia A. Kornilova
Research Center of Neurology
Email: cerebropharm@mail.ru
Russian Federation, Moscow
Marine M. Tanashyan
Research Center of Neurology
Email: cerebropharm@mail.ru
Russian Federation, Moscow
References
- Piradov M.A., Tanashyan M.M., Maksimova M.Yu. (eds.) [Stroke: modern diagnostic and treatment technologies: a guide for doctors]. Moscow, 2018. 360 p. doi: 10.24421/MP.2018.18.15909. (In Russ.)
- Tanashyan M.M., Domashenko M.A., Raskurazhev A.A. [Aspirin resistance: clinical and molecular genetic assessment methods]. Annals of Clinical and Experimental Neurology 2016; 10(1): 41–46. (In Russ.)
- Mirzoyan R.S., Naplekova P.L., Ganshina T.S. et al. [New anti-migraine agent with antiserotonin, cerebrovascular and anxiolytic activity]. Eksperimental’naya i klinicheskaya farmakologiya 2017; 80(4): 8–12. (In Russ.)
- Gryglas A., Smigiel R. Migraine and stroke: What’s the link? What to do? Curr Neurol Neurosci Rep 2017; 17: 22. doi: 10.1007/s11910-017-0729-y. PMID: 28283957.
- Kruit M.C. van Buchem M.A., Launer L.J. et al. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia 2010; 30: 129–136. doi: 10.1111/j.1468-2982.2009.01904.x. PMID: 19515125.
- Zhang S., Zhang W., Zhou G. Extended risk factors for stroke prevention. J Natl Med Assoc 2019; 111: 447–456. doi: 10.1016/j.jnma.2019.02.004. PMID: 30878142.
- Li L., Schulz U.G., Kuker W., Rothwell P.M. Age-specific association of mi- graine with cryptogenic TIA and stroke: population-based study. Neurology 2015; 85: 1444–1451. doi: 10.1212/WNL.0000000000002059. PMID: 26423431.
- Vasiliev S.A., Melkumyan A.L., Berkovsky A.L. et al. [Clinical and laboratory diagnostics of platelet dysfunction]. Moscow, 2013. 76 p. (In Russ.)
- Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927–929. doi: 10.1038/194927b0. PMID: 13871375.
- Mawet J., Kurth T., Ayata C. Migraine and stroke: in search of shared mechanisms. Cephalalgia 2015; 35: 165–181. doi: 10.1177/0333102414550106. PMID: 25228681.
- Tietjen G.E., Herial N.A., White L. et al. Migraine and biomarkers of endo- thelial activation in young women. Stroke 2009; 40: 2977–2982. DOI: 10.1161/ STROKEAHA.109.547901. PMID: 19608996.
- Dressman J.B., Nair A., Abrahamsson B. et al. Biowaiver monograph for immediate-release solid oral dosage forms: acetylsalicylic acid. J Pharm Sci 2012; 101: 2653–2667. doi: 10.1002/jps.23212. PMID: 22674043.
- Tanashyan M.M., Shabalina A.A., Lagoda O.V. et al. [Multimodal approach to the correction of neurological manifestations of chronic cerebral ischemia]. Terapevticheskiy arkhiv 2018; 90(12): 61–67. doi: 10.26442/00403660.2018.12. 000010. (In Russ.)
- Piradov M.A., Maksimova M.Yu., Tanashyan M.M. (eds.) [Stroke: step-bystep instructions]. Мoscow, 2019. 272 p. URL: https://www.rosmedlib.ru/book/ ISBN9785970449103 (In Russ.)
- Vasilieva T.M., Petrukhina G.N., Miftakhova N.T. et al. [The action of the anti-migraine drug antagonist of serotonin receptors tropoxin on platelet aggregation]. Eksperimental’naya i klinicheskaya farmakologiya 2005; 68(3): 30–33. (In Russ.)
- Bousser M.-G., Amarenco P., Chamorro A. et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011; 377: 2013–2022. DOI: 10.1016/ S0140-6736(11)60600-4. PMID: 21616527.
- Mirzoyan R.S., Ganshina T.S., Kim G.A. et al. [Translational potential of experimental pharmacology of cerebrovascular disorders]. Annals of Clinical and Experimental Neurology 2019; 13(3): 34–40. doi: 10.25692/ACEN.2019.3.5. (In Russ.)
- Krasnikov A.V., Abaimov D.A., Noskova T.Yu. et al. [The use of drug monitoring of topiramate for the individualization of preventive anti-migraine therapy]. Eksperimental’naya i klinicheskaya farmakologiya 2018; 81(7): 20–24. doi: 10.30906/0869-2092-2018-81-7-20-24. (In Russ.)
- Rau J.C., Dodick D.W. Other preventive anti-migraine treatments: ACE inhibitors, ARBs, calcium channel blockers, serotonin antagonists, and NMDA receptor antagonists. Curr Treat Options Neurol 2019; 21: 17. DOI: 10.1007/ s11940-019-0559-0. PMID: 30880363.
- Osipova V.V., Filatova E.G., Artemenko A.R. et al. [Diagnostics and treatment of migraine: recommendations of Russian experts]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 2017; 117(1): 28–42. doi: 10.17116/jnevro20171171228-42. (In Russ.)
- Fozard J.R., Kalkman H.O. 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 225–229. doi: 10.1007/BF00175026. PMID: 7824037.
- Romanycheva A.N., Ganshina T.S., Mirzoyan R.S. [Individual sensitivity to the cerebrovascular antiserotonin action of propranolol and tolfenamic acid]. Eksperimental’naya i klinicheskaya farmakologiya 1995; 58(2): 25–26. (In Russ.)
- Ganshina T.S. [Neurotransmitter mechanism of action of tropoxin in com parison with anti-migraine drugs]. Eksperimental’naya i klinicheskaya farmakologiya 2003; 66(3): 17–20. (In Russ.)
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).